RxDoctor Payments Data

Jennifer Howard, APRN

Adult Health · Ashland, KYNPI 1396235198

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 42.5% of the total.

$2,170in general payments, 2019–2025

Across 130 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$922
  • Otsuka America Pharmaceutical, Inc.$372
  • Lundbeck LLC$248
  • Idorsia Pharmaceuticals US Inc$171
  • Takeda Pharmaceuticals U.S.A., Inc.$119
  • Alkermes, Inc.$77
  • plus $262 from 9 others

What the payments were for

  • Food & beverage$2,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,170 in reported general payments places this provider in the 80th percentile of 170 adult health providers in Kentucky.

See all adult health providers in Kentucky

Medicare billing

Part B allowed, 2024
$20,678
Medicare patients
43
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$58,339
Invega SustennaPaliperidone Palmitate12$43,108
RexultiBrexpiprazole14$21,549
Lurasidone Hcl31$6,049
Quetiapine Fumarate197$3,353
Duloxetine Hcl128$3,170
Mirtazapine128$3,134
Aripiprazole95$3,129
Olanzapine115$2,728
Vilazodone Hcl15$2,474
Buspirone Hcl63$1,307
Trazodone Hcl128$1,151
Bupropion XlBupropion Hcl58$1,130
Clonazepam116$992
Divalproex Sodium55$980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$922$58,33921 claims
Johnson & JohnsonInvega Sustenna$22$43,10812 claims
Otsuka America Pharmaceutical, Inc.Rexulti$372$21,54914 claims
Almatica Pharma LLCSertraline Hcl$21$66474 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 adult health providers in Kentucky.

Other adult health in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →